Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market Growth 2026-2032
The global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market size is predicted to grow from US$ 15.07 million in 2025 to US$ 20.34 million in 2032; it is expected to grow at a CAGR of 4.4% from 2026 to 2032.
Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live is a modified live swine vaccine used for the prevention of highly pathogenic PRRS, also known as highly pathogenic porcine blue ear disease in China. Major commercial forms include monovalent vaccines based on JXA1-R, TJM-F92, GDr180, HuN4-F112 and related attenuated strains, as well as limited combination vaccines and heat-stabilized formulations containing a highly pathogenic PRRS component. Upstream inputs mainly include attenuated PRRSV seed strains, Marc-145 cells or other suitable cell substrates, culture media, serum or serum-free supplements, stabilizers, lyophilization protectants, diluents, glass vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include integrated swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease control institutions and farm technical service providers. In 2025, global production capacity is estimated at around 286 million doses, with sales volume of about 207 million doses and an average ex-factory price of approximately USD 0.070?0.081 per dose; China accounts for the dominant share of both supply and demand, while overseas sales are limited and mainly related to export registration and use in nearby swine-producing markets. This is an approval- and batch-release-driven veterinary biologics segment with a relatively small single-product market size but strong disease-control relevance for pig farms. The estimated industry gross margin in 2025 is around 45%?60%, with leading producers benefiting from larger batch scale, established distribution channels and strain resources, while smaller suppliers face greater margin volatility due to batch size, channel discounts and cold-chain costs.
The current market is mainly supported by disease prevention demand in China's swine farming sector, with supply concentrated among companies that have veterinary biologics manufacturing qualifications, strain resources, product approvals and batch-release capabilities. The category is highly regulated, and entry barriers are mainly reflected in seed strain access, cell culture processes, quality control systems, cold-chain distribution and technical service capabilities for pig farms. Because the core product is closely linked to China's control system for highly pathogenic porcine blue ear disease, only a limited number of companies have stable commercial supply globally. Competition is therefore driven more by strain routes, batch consistency, channel coverage and large-farm customer resources than by simple price competition.
On the demand side, large-scale swine farming groups, breeding farms and commercial pig farms remain the main users, and vaccination strategies are closely related to herd PRRS status, regional strain circulation, biosecurity level and hog price cycles. Large farming groups place greater emphasis on systematic immunization programs and product consistency, and generally prefer suppliers with stable batch-release records, accumulated field experience and strong technical service capabilities. Small and medium-sized farms rely more on distributors and regional veterinary service networks, with purchasing decisions more affected by price, channel recommendations and local disease pressure. Overall demand remains relatively resilient, but usage intensity varies significantly across regions and farm types.
Future development will focus on safety improvement, strain matching, process upgrading and optimization of immunization programs. Traditional modified live vaccines still have advantages in immunogenicity, accumulated use experience and market acceptance, but as farms pay more attention to disease elimination and herd health management, concerns over viral shedding, reversion risk and safety under mixed-infection conditions are becoming more prominent. Suspension culture, heat-stabilized formulations, combination vaccines and data-supported precision vaccination programs will become important paths for suppliers to strengthen competitiveness. As circulating PRRSV strains continue to evolve, companies will need stronger capabilities in field strain monitoring, clinical evaluation and product iteration.
The main growth drivers include the rising share of large-scale farming, continued investment in major swine disease control, more standardized veterinary vaccine regulation and upgrades in supplier service capabilities. Key constraints include fluctuations in hog prices that affect farm-level vaccination budgets, reduced use of live vaccines in high-health-status farms, safety concerns related to modified live vaccines, unstable protection caused by regional strain differences, and cost pressure from cold-chain logistics and batch quality control. Overall, this market is more of a stable and structurally adjusting segment than a high-growth category. Future growth will depend less on new capacity expansion and more on product upgrades, customer concentration and stronger service capabilities for large-scale pig farms.
LP Information, Inc. (LPI) ' newest research report, the ?Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Industry Forecast? looks at past sales and reviews total world Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine sales for 2026 through 2032. With Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market?
What factors are driving Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market opportunities vary by end market size?
How does Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine break out by Type, by Application?
Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live is a modified live swine vaccine used for the prevention of highly pathogenic PRRS, also known as highly pathogenic porcine blue ear disease in China. Major commercial forms include monovalent vaccines based on JXA1-R, TJM-F92, GDr180, HuN4-F112 and related attenuated strains, as well as limited combination vaccines and heat-stabilized formulations containing a highly pathogenic PRRS component. Upstream inputs mainly include attenuated PRRSV seed strains, Marc-145 cells or other suitable cell substrates, culture media, serum or serum-free supplements, stabilizers, lyophilization protectants, diluents, glass vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include integrated swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease control institutions and farm technical service providers. In 2025, global production capacity is estimated at around 286 million doses, with sales volume of about 207 million doses and an average ex-factory price of approximately USD 0.070?0.081 per dose; China accounts for the dominant share of both supply and demand, while overseas sales are limited and mainly related to export registration and use in nearby swine-producing markets. This is an approval- and batch-release-driven veterinary biologics segment with a relatively small single-product market size but strong disease-control relevance for pig farms. The estimated industry gross margin in 2025 is around 45%?60%, with leading producers benefiting from larger batch scale, established distribution channels and strain resources, while smaller suppliers face greater margin volatility due to batch size, channel discounts and cold-chain costs.
The current market is mainly supported by disease prevention demand in China's swine farming sector, with supply concentrated among companies that have veterinary biologics manufacturing qualifications, strain resources, product approvals and batch-release capabilities. The category is highly regulated, and entry barriers are mainly reflected in seed strain access, cell culture processes, quality control systems, cold-chain distribution and technical service capabilities for pig farms. Because the core product is closely linked to China's control system for highly pathogenic porcine blue ear disease, only a limited number of companies have stable commercial supply globally. Competition is therefore driven more by strain routes, batch consistency, channel coverage and large-farm customer resources than by simple price competition.
On the demand side, large-scale swine farming groups, breeding farms and commercial pig farms remain the main users, and vaccination strategies are closely related to herd PRRS status, regional strain circulation, biosecurity level and hog price cycles. Large farming groups place greater emphasis on systematic immunization programs and product consistency, and generally prefer suppliers with stable batch-release records, accumulated field experience and strong technical service capabilities. Small and medium-sized farms rely more on distributors and regional veterinary service networks, with purchasing decisions more affected by price, channel recommendations and local disease pressure. Overall demand remains relatively resilient, but usage intensity varies significantly across regions and farm types.
Future development will focus on safety improvement, strain matching, process upgrading and optimization of immunization programs. Traditional modified live vaccines still have advantages in immunogenicity, accumulated use experience and market acceptance, but as farms pay more attention to disease elimination and herd health management, concerns over viral shedding, reversion risk and safety under mixed-infection conditions are becoming more prominent. Suspension culture, heat-stabilized formulations, combination vaccines and data-supported precision vaccination programs will become important paths for suppliers to strengthen competitiveness. As circulating PRRSV strains continue to evolve, companies will need stronger capabilities in field strain monitoring, clinical evaluation and product iteration.
The main growth drivers include the rising share of large-scale farming, continued investment in major swine disease control, more standardized veterinary vaccine regulation and upgrades in supplier service capabilities. Key constraints include fluctuations in hog prices that affect farm-level vaccination budgets, reduced use of live vaccines in high-health-status farms, safety concerns related to modified live vaccines, unstable protection caused by regional strain differences, and cost pressure from cold-chain logistics and batch quality control. Overall, this market is more of a stable and structurally adjusting segment than a high-growth category. Future growth will depend less on new capacity expansion and more on product upgrades, customer concentration and stronger service capabilities for large-scale pig farms.
LP Information, Inc. (LPI) ' newest research report, the ?Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Industry Forecast? looks at past sales and reviews total world Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine sales for 2026 through 2032. With Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- JXA1-R Strain Live Vaccine
- TJM-F92 Strain Live Vaccine
- GDr180 Strain Live Vaccine
- Others
- Monovalent HP-PRRS Live Vaccine
- Bivalent Vaccine Containing HP-PRRS Component
- Others
- Small Pack (Below 20 Doses per Vial)
- Medium Pack (20?50 Doses per Vial)
- Large Pack (Above 50 Doses per Vial)
- Large-scale Integrated Pig Farming Groups
- Breeding and Multiplier Farms
- Animal Disease Control Institutions
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Dahuanong Animal Health
- Zoetis
- Jilin Teyan Biotechnology
- Qingdao Yebio Bioengineering
- Sinopharm Yangzhou Vac Biological Engineering
- Pulike Biological Engineering
- Guangdong WINSUN Bio-pharmaceutical
- Sinovetah Biological Pharmaceutical
- TECON Pharmaceutical
- Harbin Veken Biotechnology
- CAHIC
- Huapai Biotechnology Group
- Chengdu Shiji Biological Pharmaceutical
- Jilin Heyuan Biotechnology
What is the 10-year outlook for the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market?
What factors are driving Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine market opportunities vary by end market size?
How does Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Segment by Type
2.2.1 JXA1-R Strain Live Vaccine
2.2.2 TJM-F92 Strain Live Vaccine
2.2.3 GDr180 Strain Live Vaccine
2.2.4 Others
2.2.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type
2.2.5.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Type (2021-2026)
2.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Segment by Product Combination
2.3.1 Monovalent HP-PRRS Live Vaccine
2.3.2 Bivalent Vaccine Containing HP-PRRS Component
2.3.3 Others
2.3.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Product Combination
2.3.4.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Product Combination (2021-2026)
2.3.4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue and Market Share by Product Combination (2021-2026)
2.3.4.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Product Combination (2021-2026)
2.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Segment by Dose Pack Size
2.4.1 Small Pack (Below 20 Doses per Vial)
2.4.2 Medium Pack (20?50 Doses per Vial)
2.4.3 Large Pack (Above 50 Doses per Vial)
2.4.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Dose Pack Size
2.4.4.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
2.4.4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
2.4.4.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Dose Pack Size (2021-2026)
2.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Segment by Application
2.5.1 Large-scale Integrated Pig Farming Groups
2.5.2 Breeding and Multiplier Farms
2.5.3 Animal Disease Control Institutions
2.5.4 Others
2.5.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application
2.5.5.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Market Share by Application (2021-2026)
2.5.5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Breakdown Data by Company
3.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Company (2021-2026)
3.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Company
3.4 Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Location Distribution
3.4.2 Players Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HIGHLY PATHOGENIC PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME LIVE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Growth
4.4 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Growth
4.5 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Growth
4.6 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Growth
5 AMERICAS
5.1 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country
5.1.1 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026)
5.1.2 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country (2021-2026)
5.2 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026)
5.3 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Region
6.1.1 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Region (2021-2026)
6.1.2 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Region (2021-2026)
6.2 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026)
6.3 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine by Country
7.1.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026)
7.1.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country (2021-2026)
7.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026)
7.3 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine by Country
8.1.1 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
10.3 Manufacturing Process Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
10.4 Industry Chain Structure of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Distributors
11.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Customer
12 WORLD FORECAST REVIEW FOR HIGHLY PATHOGENIC PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME LIVE VACCINE BY GEOGRAPHIC REGION
12.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market Size Forecast by Region
12.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Forecast by Region (2027-2032)
12.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Forecast by Type (2027-2032)
12.7 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Dahuanong Animal Health
13.1.1 Dahuanong Animal Health Company Information
13.1.2 Dahuanong Animal Health Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.1.3 Dahuanong Animal Health Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Dahuanong Animal Health Main Business Overview
13.1.5 Dahuanong Animal Health Latest Developments
13.2 Zoetis
13.2.1 Zoetis Company Information
13.2.2 Zoetis Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.2.3 Zoetis Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Zoetis Main Business Overview
13.2.5 Zoetis Latest Developments
13.3 Jilin Teyan Biotechnology
13.3.1 Jilin Teyan Biotechnology Company Information
13.3.2 Jilin Teyan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.3.3 Jilin Teyan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Jilin Teyan Biotechnology Main Business Overview
13.3.5 Jilin Teyan Biotechnology Latest Developments
13.4 Qingdao Yebio Bioengineering
13.4.1 Qingdao Yebio Bioengineering Company Information
13.4.2 Qingdao Yebio Bioengineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.4.3 Qingdao Yebio Bioengineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Qingdao Yebio Bioengineering Main Business Overview
13.4.5 Qingdao Yebio Bioengineering Latest Developments
13.5 Sinopharm Yangzhou Vac Biological Engineering
13.5.1 Sinopharm Yangzhou Vac Biological Engineering Company Information
13.5.2 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.5.3 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sinopharm Yangzhou Vac Biological Engineering Main Business Overview
13.5.5 Sinopharm Yangzhou Vac Biological Engineering Latest Developments
13.6 Pulike Biological Engineering
13.6.1 Pulike Biological Engineering Company Information
13.6.2 Pulike Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.6.3 Pulike Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Pulike Biological Engineering Main Business Overview
13.6.5 Pulike Biological Engineering Latest Developments
13.7 Guangdong WINSUN Bio-pharmaceutical
13.7.1 Guangdong WINSUN Bio-pharmaceutical Company Information
13.7.2 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.7.3 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Guangdong WINSUN Bio-pharmaceutical Main Business Overview
13.7.5 Guangdong WINSUN Bio-pharmaceutical Latest Developments
13.8 Sinovetah Biological Pharmaceutical
13.8.1 Sinovetah Biological Pharmaceutical Company Information
13.8.2 Sinovetah Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.8.3 Sinovetah Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Sinovetah Biological Pharmaceutical Main Business Overview
13.8.5 Sinovetah Biological Pharmaceutical Latest Developments
13.9 TECON Pharmaceutical
13.9.1 TECON Pharmaceutical Company Information
13.9.2 TECON Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.9.3 TECON Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 TECON Pharmaceutical Main Business Overview
13.9.5 TECON Pharmaceutical Latest Developments
13.10 Harbin Veken Biotechnology
13.10.1 Harbin Veken Biotechnology Company Information
13.10.2 Harbin Veken Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.10.3 Harbin Veken Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Harbin Veken Biotechnology Main Business Overview
13.10.5 Harbin Veken Biotechnology Latest Developments
13.11 CAHIC
13.11.1 CAHIC Company Information
13.11.2 CAHIC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.11.3 CAHIC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 CAHIC Main Business Overview
13.11.5 CAHIC Latest Developments
13.12 Huapai Biotechnology Group
13.12.1 Huapai Biotechnology Group Company Information
13.12.2 Huapai Biotechnology Group Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.12.3 Huapai Biotechnology Group Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Huapai Biotechnology Group Main Business Overview
13.12.5 Huapai Biotechnology Group Latest Developments
13.13 Chengdu Shiji Biological Pharmaceutical
13.13.1 Chengdu Shiji Biological Pharmaceutical Company Information
13.13.2 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.13.3 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Chengdu Shiji Biological Pharmaceutical Main Business Overview
13.13.5 Chengdu Shiji Biological Pharmaceutical Latest Developments
13.14 Jilin Heyuan Biotechnology
13.14.1 Jilin Heyuan Biotechnology Company Information
13.14.2 Jilin Heyuan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.14.3 Jilin Heyuan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Jilin Heyuan Biotechnology Main Business Overview
13.14.5 Jilin Heyuan Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Segment by Type
2.2.1 JXA1-R Strain Live Vaccine
2.2.2 TJM-F92 Strain Live Vaccine
2.2.3 GDr180 Strain Live Vaccine
2.2.4 Others
2.2.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type
2.2.5.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Type (2021-2026)
2.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Segment by Product Combination
2.3.1 Monovalent HP-PRRS Live Vaccine
2.3.2 Bivalent Vaccine Containing HP-PRRS Component
2.3.3 Others
2.3.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Product Combination
2.3.4.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Product Combination (2021-2026)
2.3.4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue and Market Share by Product Combination (2021-2026)
2.3.4.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Product Combination (2021-2026)
2.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Segment by Dose Pack Size
2.4.1 Small Pack (Below 20 Doses per Vial)
2.4.2 Medium Pack (20?50 Doses per Vial)
2.4.3 Large Pack (Above 50 Doses per Vial)
2.4.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Dose Pack Size
2.4.4.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
2.4.4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
2.4.4.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Dose Pack Size (2021-2026)
2.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Segment by Application
2.5.1 Large-scale Integrated Pig Farming Groups
2.5.2 Breeding and Multiplier Farms
2.5.3 Animal Disease Control Institutions
2.5.4 Others
2.5.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application
2.5.5.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Market Share by Application (2021-2026)
2.5.5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Breakdown Data by Company
3.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Company (2021-2026)
3.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Company
3.4 Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Location Distribution
3.4.2 Players Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HIGHLY PATHOGENIC PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME LIVE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Growth
4.4 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Growth
4.5 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Growth
4.6 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Growth
5 AMERICAS
5.1 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country
5.1.1 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026)
5.1.2 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country (2021-2026)
5.2 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026)
5.3 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Region
6.1.1 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Region (2021-2026)
6.1.2 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Region (2021-2026)
6.2 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026)
6.3 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine by Country
7.1.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026)
7.1.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country (2021-2026)
7.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026)
7.3 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine by Country
8.1.1 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
10.3 Manufacturing Process Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
10.4 Industry Chain Structure of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Distributors
11.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Customer
12 WORLD FORECAST REVIEW FOR HIGHLY PATHOGENIC PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME LIVE VACCINE BY GEOGRAPHIC REGION
12.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market Size Forecast by Region
12.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Forecast by Region (2027-2032)
12.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Forecast by Type (2027-2032)
12.7 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Dahuanong Animal Health
13.1.1 Dahuanong Animal Health Company Information
13.1.2 Dahuanong Animal Health Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.1.3 Dahuanong Animal Health Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Dahuanong Animal Health Main Business Overview
13.1.5 Dahuanong Animal Health Latest Developments
13.2 Zoetis
13.2.1 Zoetis Company Information
13.2.2 Zoetis Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.2.3 Zoetis Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Zoetis Main Business Overview
13.2.5 Zoetis Latest Developments
13.3 Jilin Teyan Biotechnology
13.3.1 Jilin Teyan Biotechnology Company Information
13.3.2 Jilin Teyan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.3.3 Jilin Teyan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Jilin Teyan Biotechnology Main Business Overview
13.3.5 Jilin Teyan Biotechnology Latest Developments
13.4 Qingdao Yebio Bioengineering
13.4.1 Qingdao Yebio Bioengineering Company Information
13.4.2 Qingdao Yebio Bioengineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.4.3 Qingdao Yebio Bioengineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Qingdao Yebio Bioengineering Main Business Overview
13.4.5 Qingdao Yebio Bioengineering Latest Developments
13.5 Sinopharm Yangzhou Vac Biological Engineering
13.5.1 Sinopharm Yangzhou Vac Biological Engineering Company Information
13.5.2 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.5.3 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sinopharm Yangzhou Vac Biological Engineering Main Business Overview
13.5.5 Sinopharm Yangzhou Vac Biological Engineering Latest Developments
13.6 Pulike Biological Engineering
13.6.1 Pulike Biological Engineering Company Information
13.6.2 Pulike Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.6.3 Pulike Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Pulike Biological Engineering Main Business Overview
13.6.5 Pulike Biological Engineering Latest Developments
13.7 Guangdong WINSUN Bio-pharmaceutical
13.7.1 Guangdong WINSUN Bio-pharmaceutical Company Information
13.7.2 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.7.3 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Guangdong WINSUN Bio-pharmaceutical Main Business Overview
13.7.5 Guangdong WINSUN Bio-pharmaceutical Latest Developments
13.8 Sinovetah Biological Pharmaceutical
13.8.1 Sinovetah Biological Pharmaceutical Company Information
13.8.2 Sinovetah Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.8.3 Sinovetah Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Sinovetah Biological Pharmaceutical Main Business Overview
13.8.5 Sinovetah Biological Pharmaceutical Latest Developments
13.9 TECON Pharmaceutical
13.9.1 TECON Pharmaceutical Company Information
13.9.2 TECON Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.9.3 TECON Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 TECON Pharmaceutical Main Business Overview
13.9.5 TECON Pharmaceutical Latest Developments
13.10 Harbin Veken Biotechnology
13.10.1 Harbin Veken Biotechnology Company Information
13.10.2 Harbin Veken Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.10.3 Harbin Veken Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Harbin Veken Biotechnology Main Business Overview
13.10.5 Harbin Veken Biotechnology Latest Developments
13.11 CAHIC
13.11.1 CAHIC Company Information
13.11.2 CAHIC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.11.3 CAHIC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 CAHIC Main Business Overview
13.11.5 CAHIC Latest Developments
13.12 Huapai Biotechnology Group
13.12.1 Huapai Biotechnology Group Company Information
13.12.2 Huapai Biotechnology Group Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.12.3 Huapai Biotechnology Group Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Huapai Biotechnology Group Main Business Overview
13.12.5 Huapai Biotechnology Group Latest Developments
13.13 Chengdu Shiji Biological Pharmaceutical
13.13.1 Chengdu Shiji Biological Pharmaceutical Company Information
13.13.2 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.13.3 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Chengdu Shiji Biological Pharmaceutical Main Business Overview
13.13.5 Chengdu Shiji Biological Pharmaceutical Latest Developments
13.14 Jilin Heyuan Biotechnology
13.14.1 Jilin Heyuan Biotechnology Company Information
13.14.2 Jilin Heyuan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
13.14.3 Jilin Heyuan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Jilin Heyuan Biotechnology Main Business Overview
13.14.5 Jilin Heyuan Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of JXA1-R Strain Live Vaccine
Table 4. Major Players of TJM-F92 Strain Live Vaccine
Table 5. Major Players of GDr180 Strain Live Vaccine
Table 6. Major Players of Others
Table 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 8. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Major Players of Monovalent HP-PRRS Live Vaccine
Table 13. Major Players of Bivalent Vaccine Containing HP-PRRS Component
Table 14. Major Players of Others
Table 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Product Combination (2021-2026) & (K Dose)
Table 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Product Combination (2021-2026)
Table 17. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Product Combination (2021-2026) & ($ million)
Table 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Product Combination (2021-2026)
Table 19. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Product Combination (2021-2026) & (US$/Dose)
Table 20. Major Players of Small Pack (Below 20 Doses per Vial)
Table 21. Major Players of Medium Pack (20?50 Doses per Vial)
Table 22. Major Players of Large Pack (Above 50 Doses per Vial)
Table 23. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)
Table 24. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
Table 25. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Dose Pack Size (2021-2026) & ($ million)
Table 26. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Table 27. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 28. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale by Application (2021-2026) & (K Dose)
Table 29. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Market Share by Application (2021-2026)
Table 30. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Application (2021-2026) & ($ million)
Table 31. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Application (2021-2026)
Table 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 33. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Company (2021-2026) & (K Dose)
Table 34. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Company (2021-2026)
Table 35. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 36. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Company (2021-2026)
Table 37. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 38. Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Producing Area Distribution and Sales Area
Table 39. Players Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Products Offered
Table 40. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 41. New Products and Potential Entrants
Table 42. Market M&A Activity & Strategy
Table 43. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 44. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share Geographic Region (2021-2026)
Table 45. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 46. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 47. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 48. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country/Region (2021-2026)
Table 49. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 50. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 51. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 52. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country (2021-2026)
Table 53. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 54. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 55. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 56. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Region (2021-2026) & (K Dose)
Table 57. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Region (2021-2026)
Table 58. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 59. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 60. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 61. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 62. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 63. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 64. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 65. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 66. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Country (2021-2026)
Table 67. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 68. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 69. Key Market Drivers & Growth Opportunities of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Table 70. Key Market Challenges & Risks of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Table 71. Key Industry Trends of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Table 72. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Distributors List
Table 75. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Customer List
Table 76. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 77. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 79. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 81. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 85. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 87. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 88. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 89. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 90. Dahuanong Animal Health Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 91. Dahuanong Animal Health Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 92. Dahuanong Animal Health Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 93. Dahuanong Animal Health Main Business
Table 94. Dahuanong Animal Health Latest Developments
Table 95. Zoetis Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 96. Zoetis Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 97. Zoetis Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. Zoetis Main Business
Table 99. Zoetis Latest Developments
Table 100. Jilin Teyan Biotechnology Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 101. Jilin Teyan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 102. Jilin Teyan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 103. Jilin Teyan Biotechnology Main Business
Table 104. Jilin Teyan Biotechnology Latest Developments
Table 105. Qingdao Yebio Bioengineering Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 106. Qingdao Yebio Bioengineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 107. Qingdao Yebio Bioengineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. Qingdao Yebio Bioengineering Main Business
Table 109. Qingdao Yebio Bioengineering Latest Developments
Table 110. Sinopharm Yangzhou Vac Biological Engineering Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 111. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 112. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 113. Sinopharm Yangzhou Vac Biological Engineering Main Business
Table 114. Sinopharm Yangzhou Vac Biological Engineering Latest Developments
Table 115. Pulike Biological Engineering Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 116. Pulike Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 117. Pulike Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 118. Pulike Biological Engineering Main Business
Table 119. Pulike Biological Engineering Latest Developments
Table 120. Guangdong WINSUN Bio-pharmaceutical Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 121. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 122. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 123. Guangdong WINSUN Bio-pharmaceutical Main Business
Table 124. Guangdong WINSUN Bio-pharmaceutical Latest Developments
Table 125. Sinovetah Biological Pharmaceutical Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 126. Sinovetah Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 127. Sinovetah Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 128. Sinovetah Biological Pharmaceutical Main Business
Table 129. Sinovetah Biological Pharmaceutical Latest Developments
Table 130. TECON Pharmaceutical Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 131. TECON Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 132. TECON Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 133. TECON Pharmaceutical Main Business
Table 134. TECON Pharmaceutical Latest Developments
Table 135. Harbin Veken Biotechnology Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 136. Harbin Veken Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 137. Harbin Veken Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 138. Harbin Veken Biotechnology Main Business
Table 139. Harbin Veken Biotechnology Latest Developments
Table 140. CAHIC Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 141. CAHIC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 142. CAHIC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 143. CAHIC Main Business
Table 144. CAHIC Latest Developments
Table 145. Huapai Biotechnology Group Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 146. Huapai Biotechnology Group Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 147. Huapai Biotechnology Group Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 148. Huapai Biotechnology Group Main Business
Table 149. Huapai Biotechnology Group Latest Developments
Table 150. Chengdu Shiji Biological Pharmaceutical Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 151. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 152. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 153. Chengdu Shiji Biological Pharmaceutical Main Business
Table 154. Chengdu Shiji Biological Pharmaceutical Latest Developments
Table 155. Jilin Heyuan Biotechnology Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 156. Jilin Heyuan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 157. Jilin Heyuan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 158. Jilin Heyuan Biotechnology Main Business
Table 159. Jilin Heyuan Biotechnology Latest Developments
Table 1. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of JXA1-R Strain Live Vaccine
Table 4. Major Players of TJM-F92 Strain Live Vaccine
Table 5. Major Players of GDr180 Strain Live Vaccine
Table 6. Major Players of Others
Table 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 8. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Major Players of Monovalent HP-PRRS Live Vaccine
Table 13. Major Players of Bivalent Vaccine Containing HP-PRRS Component
Table 14. Major Players of Others
Table 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Product Combination (2021-2026) & (K Dose)
Table 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Product Combination (2021-2026)
Table 17. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Product Combination (2021-2026) & ($ million)
Table 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Product Combination (2021-2026)
Table 19. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Product Combination (2021-2026) & (US$/Dose)
Table 20. Major Players of Small Pack (Below 20 Doses per Vial)
Table 21. Major Players of Medium Pack (20?50 Doses per Vial)
Table 22. Major Players of Large Pack (Above 50 Doses per Vial)
Table 23. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)
Table 24. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
Table 25. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Dose Pack Size (2021-2026) & ($ million)
Table 26. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Table 27. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 28. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale by Application (2021-2026) & (K Dose)
Table 29. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Market Share by Application (2021-2026)
Table 30. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Application (2021-2026) & ($ million)
Table 31. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Application (2021-2026)
Table 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 33. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Company (2021-2026) & (K Dose)
Table 34. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Company (2021-2026)
Table 35. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 36. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Company (2021-2026)
Table 37. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 38. Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Producing Area Distribution and Sales Area
Table 39. Players Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Products Offered
Table 40. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 41. New Products and Potential Entrants
Table 42. Market M&A Activity & Strategy
Table 43. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 44. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share Geographic Region (2021-2026)
Table 45. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 46. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 47. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 48. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country/Region (2021-2026)
Table 49. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 50. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 51. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 52. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country (2021-2026)
Table 53. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 54. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 55. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 56. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Region (2021-2026) & (K Dose)
Table 57. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Region (2021-2026)
Table 58. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 59. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 60. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 61. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 62. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 63. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 64. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 65. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 66. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Country (2021-2026)
Table 67. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 68. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 69. Key Market Drivers & Growth Opportunities of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Table 70. Key Market Challenges & Risks of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Table 71. Key Industry Trends of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Table 72. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Distributors List
Table 75. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Customer List
Table 76. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 77. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 79. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 81. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 85. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 87. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 88. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 89. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 90. Dahuanong Animal Health Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 91. Dahuanong Animal Health Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 92. Dahuanong Animal Health Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 93. Dahuanong Animal Health Main Business
Table 94. Dahuanong Animal Health Latest Developments
Table 95. Zoetis Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 96. Zoetis Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 97. Zoetis Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. Zoetis Main Business
Table 99. Zoetis Latest Developments
Table 100. Jilin Teyan Biotechnology Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 101. Jilin Teyan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 102. Jilin Teyan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 103. Jilin Teyan Biotechnology Main Business
Table 104. Jilin Teyan Biotechnology Latest Developments
Table 105. Qingdao Yebio Bioengineering Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 106. Qingdao Yebio Bioengineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 107. Qingdao Yebio Bioengineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. Qingdao Yebio Bioengineering Main Business
Table 109. Qingdao Yebio Bioengineering Latest Developments
Table 110. Sinopharm Yangzhou Vac Biological Engineering Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 111. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 112. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 113. Sinopharm Yangzhou Vac Biological Engineering Main Business
Table 114. Sinopharm Yangzhou Vac Biological Engineering Latest Developments
Table 115. Pulike Biological Engineering Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 116. Pulike Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 117. Pulike Biological Engineering Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 118. Pulike Biological Engineering Main Business
Table 119. Pulike Biological Engineering Latest Developments
Table 120. Guangdong WINSUN Bio-pharmaceutical Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 121. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 122. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 123. Guangdong WINSUN Bio-pharmaceutical Main Business
Table 124. Guangdong WINSUN Bio-pharmaceutical Latest Developments
Table 125. Sinovetah Biological Pharmaceutical Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 126. Sinovetah Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 127. Sinovetah Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 128. Sinovetah Biological Pharmaceutical Main Business
Table 129. Sinovetah Biological Pharmaceutical Latest Developments
Table 130. TECON Pharmaceutical Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 131. TECON Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 132. TECON Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 133. TECON Pharmaceutical Main Business
Table 134. TECON Pharmaceutical Latest Developments
Table 135. Harbin Veken Biotechnology Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 136. Harbin Veken Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 137. Harbin Veken Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 138. Harbin Veken Biotechnology Main Business
Table 139. Harbin Veken Biotechnology Latest Developments
Table 140. CAHIC Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 141. CAHIC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 142. CAHIC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 143. CAHIC Main Business
Table 144. CAHIC Latest Developments
Table 145. Huapai Biotechnology Group Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 146. Huapai Biotechnology Group Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 147. Huapai Biotechnology Group Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 148. Huapai Biotechnology Group Main Business
Table 149. Huapai Biotechnology Group Latest Developments
Table 150. Chengdu Shiji Biological Pharmaceutical Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 151. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 152. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 153. Chengdu Shiji Biological Pharmaceutical Main Business
Table 154. Chengdu Shiji Biological Pharmaceutical Latest Developments
Table 155. Jilin Heyuan Biotechnology Basic Information, Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 156. Jilin Heyuan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Product Portfolios and Specifications
Table 157. Jilin Heyuan Biotechnology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 158. Jilin Heyuan Biotechnology Main Business
Table 159. Jilin Heyuan Biotechnology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Figure 2. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of JXA1-R Strain Live Vaccine
Figure 12. Product Picture of TJM-F92 Strain Live Vaccine
Figure 13. Product Picture of GDr180 Strain Live Vaccine
Figure 14. Product Picture of Others
Figure 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type in 2026
Figure 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Monovalent HP-PRRS Live Vaccine
Figure 18. Product Picture of Bivalent Vaccine Containing HP-PRRS Component
Figure 19. Product Picture of Others
Figure 20. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Product Combination in 2026
Figure 21. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Product Combination (2021-2026)
Figure 22. Product Picture of Small Pack (Below 20 Doses per Vial)
Figure 23. Product Picture of Medium Pack (20?50 Doses per Vial)
Figure 24. Product Picture of Large Pack (Above 50 Doses per Vial)
Figure 25. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Dose Pack Size in 2026
Figure 26. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Figure 27. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Consumed in Large-scale Integrated Pig Farming Groups
Figure 28. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market: Large-scale Integrated Pig Farming Groups (2021-2026) & (K Dose)
Figure 29. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Consumed in Breeding and Multiplier Farms
Figure 30. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market: Breeding and Multiplier Farms (2021-2026) & (K Dose)
Figure 31. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Consumed in Animal Disease Control Institutions
Figure 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market: Animal Disease Control Institutions (2021-2026) & (K Dose)
Figure 33. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Consumed in Others
Figure 34. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market: Others (2021-2026) & (K Dose)
Figure 35. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Market Share by Application (2025)
Figure 36. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Application in 2025
Figure 37. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Company in 2025 (K Dose)
Figure 38. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Company in 2025
Figure 39. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Company in 2025 ($ millions)
Figure 40. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Company in 2025
Figure 41. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 42. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Geographic Region in 2025
Figure 43. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales 2021-2026 (K Dose)
Figure 44. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue 2021-2026 ($ millions)
Figure 45. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales 2021-2026 (K Dose)
Figure 46. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue 2021-2026 ($ millions)
Figure 47. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales 2021-2026 (K Dose)
Figure 48. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue 2021-2026 ($ millions)
Figure 49. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales 2021-2026 (K Dose)
Figure 50. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue 2021-2026 ($ millions)
Figure 51. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country in 2025
Figure 52. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 53. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
Figure 54. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Application (2021-2026)
Figure 55. United States Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Mexico Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Brazil Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Region in 2025
Figure 60. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Region (2021-2026)
Figure 61. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
Figure 62. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Application (2021-2026)
Figure 63. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Japan Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. South Korea Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Southeast Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. India Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Australia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. China Taiwan Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country in 2025
Figure 71. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 72. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
Figure 73. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Application (2021-2026)
Figure 74. Germany Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. France Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. UK Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Italy Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Russia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 79. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country (2021-2026)
Figure 80. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
Figure 81. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Application (2021-2026)
Figure 82. Egypt Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. South Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Israel Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. Turkey Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. GCC Countries Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 87. Manufacturing Cost Structure Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine in 2026
Figure 88. Manufacturing Process Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Figure 89. Industry Chain Structure of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Figure 90. Channels of Distribution
Figure 91. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Forecast by Region (2027-2032)
Figure 92. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 93. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 94. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Figure 1. Picture of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Figure 2. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of JXA1-R Strain Live Vaccine
Figure 12. Product Picture of TJM-F92 Strain Live Vaccine
Figure 13. Product Picture of GDr180 Strain Live Vaccine
Figure 14. Product Picture of Others
Figure 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type in 2026
Figure 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Monovalent HP-PRRS Live Vaccine
Figure 18. Product Picture of Bivalent Vaccine Containing HP-PRRS Component
Figure 19. Product Picture of Others
Figure 20. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Product Combination in 2026
Figure 21. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Product Combination (2021-2026)
Figure 22. Product Picture of Small Pack (Below 20 Doses per Vial)
Figure 23. Product Picture of Medium Pack (20?50 Doses per Vial)
Figure 24. Product Picture of Large Pack (Above 50 Doses per Vial)
Figure 25. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Dose Pack Size in 2026
Figure 26. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Figure 27. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Consumed in Large-scale Integrated Pig Farming Groups
Figure 28. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market: Large-scale Integrated Pig Farming Groups (2021-2026) & (K Dose)
Figure 29. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Consumed in Breeding and Multiplier Farms
Figure 30. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market: Breeding and Multiplier Farms (2021-2026) & (K Dose)
Figure 31. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Consumed in Animal Disease Control Institutions
Figure 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market: Animal Disease Control Institutions (2021-2026) & (K Dose)
Figure 33. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Consumed in Others
Figure 34. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Market: Others (2021-2026) & (K Dose)
Figure 35. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sale Market Share by Application (2025)
Figure 36. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Application in 2025
Figure 37. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales by Company in 2025 (K Dose)
Figure 38. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Company in 2025
Figure 39. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue by Company in 2025 ($ millions)
Figure 40. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Company in 2025
Figure 41. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 42. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Geographic Region in 2025
Figure 43. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales 2021-2026 (K Dose)
Figure 44. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue 2021-2026 ($ millions)
Figure 45. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales 2021-2026 (K Dose)
Figure 46. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue 2021-2026 ($ millions)
Figure 47. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales 2021-2026 (K Dose)
Figure 48. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue 2021-2026 ($ millions)
Figure 49. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales 2021-2026 (K Dose)
Figure 50. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue 2021-2026 ($ millions)
Figure 51. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country in 2025
Figure 52. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 53. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
Figure 54. Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Application (2021-2026)
Figure 55. United States Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Mexico Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Brazil Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Region in 2025
Figure 60. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Region (2021-2026)
Figure 61. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
Figure 62. APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Application (2021-2026)
Figure 63. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Japan Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. South Korea Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Southeast Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. India Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Australia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. China Taiwan Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country in 2025
Figure 71. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 72. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
Figure 73. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Application (2021-2026)
Figure 74. Germany Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. France Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. UK Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Italy Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Russia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 79. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Country (2021-2026)
Figure 80. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Type (2021-2026)
Figure 81. Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share by Application (2021-2026)
Figure 82. Egypt Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. South Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Israel Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. Turkey Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. GCC Countries Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 87. Manufacturing Cost Structure Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine in 2026
Figure 88. Manufacturing Process Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Figure 89. Industry Chain Structure of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
Figure 90. Channels of Distribution
Figure 91. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Forecast by Region (2027-2032)
Figure 92. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 93. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 94. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Live Vaccine
